Adherence evaluation of endocrine treatment in breast cancer: methodological aspects

Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)

(2011) Anne Oberguggenberger et al.   BREAST CANCER RESEARCH AND TREATMENT

Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer

(2011) L Huiart et al.   BRITISH JOURNAL OF CANCER

Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study

(2010) Beate Beer et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

(2010) Dawn L. Hershman et al.   BREAST CANCER RESEARCH AND TREATMENT

Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene

(2010) V. Ziller et al.   CLIMACTERIC

Adherence to Medicines in the Older-Aged with Chronic Conditions

(2010) Sheila A. Doggrell   DRUGS & AGING

Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients

(2010) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessment of Clinician Awareness of Nonadherence Using a New Structured Rating Scale

(2010) Carol D. Clayton et al.   Journal of Psychiatric Practice

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY

Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer

(2009) V. Ziller et al.   ANNALS OF ONCOLOGY